Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.


Yildiz İ. , Sen F., Basaran M., Ekenel M., Agaoglu F. , Darendeliler E., ...More

Japanese journal of clinical oncology, vol.41, no.12, pp.1380-7, 2011 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 12
  • Publication Date: 2011
  • Doi Number: 10.1093/jjco/hyr151
  • Title of Journal : Japanese journal of clinical oncology
  • Page Numbers: pp.1380-7

Abstract

Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.